LFST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
LifeStance Health Group Inc (LFST) is not a strong buy for a beginner, long-term investor at this moment. While the company has positive revenue growth and analyst sentiment, the recent insider selling, negative price action, and declining net income suggest caution. The lack of strong proprietary trading signals further supports holding off on immediate investment.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 41.244, suggesting no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock has broken below its key support level (S1: 6.796), signaling potential weakness. Overall, the technical indicators are mixed.
Analysts have raised price targets consistently, with the latest targets ranging from $9 to $
Strong Q4 revenue growth of 17% YoY and a positive outlook for
Increased clinician productivity and new AI tools improving operational efficiency.
Insider selling has increased significantly by 132.67% over the last month.
Recent announcement of 25 million shares being offered by stockholders, which could dilute existing shares.
Net income and EPS have dropped significantly YoY, indicating profitability challenges.
In Q4 2025, revenue grew by 17.43% YoY to $382.2 million, showing strong top-line growth. However, net income dropped by -264.06% YoY to $11.67 million, and EPS fell by -250% YoY to $0.03, reflecting significant profitability issues.
Analysts are bullish, with multiple firms raising price targets recently (KeyBanc: $9, BMO Capital: $10, BTIG: $11). The consensus is positive, citing strong revenue growth, clinician productivity, and macroeconomic tailwinds in the mental health sector.
